image
Healthcare - Medical - Pharmaceuticals - NASDAQ - US
$ 23.48
-1.9 %
$ 1.07 B
Market Cap
-10.31
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one LFMDP stock under the worst case scenario is HIDDEN Compared to the current market price of 23.5 USD, LifeMD, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one LFMDP stock under the base case scenario is HIDDEN Compared to the current market price of 23.5 USD, LifeMD, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one LFMDP stock under the best case scenario is HIDDEN Compared to the current market price of 23.5 USD, LifeMD, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LFMDP

image
$26.0$26.0$25.5$25.5$25.0$25.0$24.5$24.5$24.0$24.0$23.5$23.5$23.0$23.0$22.5$22.5$22.0$22.0$21.5$21.5$21.0$21.0$20.5$20.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
212 M REVENUE
39.27%
-16.1 M OPERATING INCOME
-11.43%
-18.9 M NET INCOME
8.32%
17.5 M OPERATING CASH FLOW
98.56%
-11.5 M INVESTING CASH FLOW
-32.10%
-4.12 M FINANCING CASH FLOW
-14.15%
65.7 M REVENUE
2.25%
2.54 M OPERATING INCOME
149.74%
1.92 M NET INCOME
1903.53%
3.07 M OPERATING CASH FLOW
95.64%
-2.87 M INVESTING CASH FLOW
-5.39%
-813 K FINANCING CASH FLOW
43.18%
Balance Sheet LifeMD, Inc.
image
Current Assets 48.7 M
Cash & Short-Term Investments 35 M
Receivables 8.22 M
Other Current Assets 5.51 M
Non-Current Assets 23.7
Long-Term Investments 0
PP&E 6.4
Other Non-Current Assets 17.3
26.98 %73.02 %Total Assets$23.7t
Current Liabilities 60.3 M
Accounts Payable 16 M
Short-Term Debt 8.95 M
Other Current Liabilities 35.3 M
Non-Current Liabilities 16.3 M
Long-Term Debt 16.2 M
Other Non-Current Liabilities 100 K
20.93 %11.70 %46.13 %21.11 %Total Liabilities$76.5m
EFFICIENCY
Earnings Waterfall LifeMD, Inc.
image
Revenue 212 M
Cost Of Revenue -29.9 M
Gross Profit 242 M
Operating Expenses 194 M
Operating Income -16.1 M
Other Expenses 2.74 M
Net Income -18.9 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)212m30m242m(194m)(16m)(3m)(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
114.10% GROSS MARGIN
114.10%
-7.60% OPERATING MARGIN
-7.60%
-8.89% NET MARGIN
-8.89%
0.00% ROE
0.00%
-26.06% ROA
-26.06%
-0.00% ROIC
-0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis LifeMD, Inc.
image
10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -18.9 M
Depreciation & Amortization 9.49 M
Capital Expenditures -11.5 M
Stock-Based Compensation 12.2 M
Change in Working Capital 12.6 M
Others 24.2 M
Free Cash Flow 5.98 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets LifeMD, Inc.
image
LFMDP has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.33% DIVIDEND YIELD
0.555 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.500002.500002.000002.000001.500001.500001.000001.000000.500000.500000.000000.000000.622480.554690.554690.554690.554690.554690.554690.554690.554690.554690.554690.554692.290.554692.220.554692.221.1120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership LifeMD, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy® Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter globenewswire.com - 3 weeks ago
LifeMD to Participate in Three Investor Conferences During May NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May: globenewswire.com - 1 month ago
LifeMD, Inc. (LFMD) Q1 2025 Earnings Call Transcript LifeMD, Inc. (NASDAQ:LFMD ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Justin Schreiber - Chairman and CEO Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Sarah James - Cantor Fitzgerald Steve Dechert - KeyBanc Steven Valiquette - Mizuho Securities Yi Chen - H.C. Wainwright Anderson Schock - B. seekingalpha.com - 1 month ago
LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD's virtual care platform. globenewswire.com - 1 month ago
LifeMD to Report First Quarter 2025 Financial Results on May 6 NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. globenewswire.com - 1 month ago
LifeMD to Participate in the 24th Annual Needham Virtual Healthcare Conference NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors. globenewswire.com - 2 months ago
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2025, to holders of record at the close of business on April 4, 2025. globenewswire.com - 2 months ago
LifeMD, Inc. (LFMD) Q4 2024 Earnings Call Transcript LifeMD, Inc. (NASDAQ:LFMD ) Q4 2024 Results Conference Call March 10, 2025 4:30 PM ET Company Participants Justin Schreiber - Chairman and Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Steve Dechert - KeyBanc Brooks O'Neil - Lake Street Capital Markets Steven Valiquette - Mizuho Securities Alex Fuhrman - Craig-Hallum Capital Group Sarah James - Cantor Anderson Schock - B. Riley Securities Operator Good afternoon. seekingalpha.com - 3 months ago
LifeMD Reports Fourth Quarter 2024 Results Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60% Adjusted EBITDA increased 78% to $9.0 million Telehealth adjusted EBITDA increased 396% to $5.9 million Full-year cash flow from operations increased 99% to $17.5 million and generated positive full-year net cash flow Exited 2024 with over $35 million in cash Introduces 2025 guidance for consolidated revenue of $265 million to $275 million and consolidated adjusted EBITDA of $30 million to $32 million Conference call begins at 4:30 p.m. Eastern time today NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and 12 months ended December 31, 2024. globenewswire.com - 3 months ago
LifeMD to Participate in the KeyBanc Capital Markets Healthcare Forum NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the KeyBanc Capital Markets Healthcare Forum being held virtually on March 18-19, 2025. Management will participate in a fireside chat on Tuesday, March 18th at 11:15 a.m. Eastern time and will hold one-on-one meetings throughout the conference. globenewswire.com - 3 months ago
LifeMD to Report Fourth Quarter 2024 Financial Results on March 10 NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on March 10, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. globenewswire.com - 3 months ago
LifeMD® Announces Entry Into the Behavioral Health Market Expansion to Include Teletherapy, Psychiatry and Medication Management Behavioral Health Offering to be Led by Industry Veteran Julian Cohen NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its expansion into the behavioral health market. This strategic move broadens LifeMD's service offerings to include teletherapy, psychiatry and medication management for common mental health conditions. globenewswire.com - 3 months ago
8. Profile Summary

LifeMD, Inc. LFMDP

image
COUNTRY US
INDUSTRY Medical - Pharmaceuticals
MARKET CAP $ 1.07 B
Dividend Yield 0.33%
Description LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Contact 236 Fifth Avenue, New York City, NY, 10001 https://www.lifemd.com
IPO Date Oct. 5, 2021
Employees 304
Officers Ms. Maria E. Stan CPA Chief Accounting Officer & Controller Mr. Eric H. Yecies Chief Legal Officer, General Counsel & Corporate Secretary Mr. Stefan Galluppi Chief Innovation Officer Mr. Nicholas P. Alvarez Chief Acquisition Officer & Head of Customer Acquisition Mr. Dennis Wijnker Chief Technology Officer Mr. Marc Benathen Chief Financial Officer Mr. James Porte Senior Vice President of Patient Experience Ms. Jessica Friedeman Chief Marketing Officer Mr. Shane Biffar Chief Compliance Officer & Deputy General Counsel Mr. Justin Schreiber Chairman & Chief Executive Officer